Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -16.35% | 6.16% | 27.82% | 61.24% | 143.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.35% | 6.16% | 27.82% | 61.24% | 143.30% |
| Cost of Revenue | 56.28% | 60.29% | 82.95% | 47.82% | 75.09% |
| Gross Profit | -474.40% | -268.57% | -428.07% | 434.42% | 267.05% |
| SG&A Expenses | -39.54% | -28.36% | -12.36% | -8.30% | -5.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.46% | 3.07% | 19.38% | 7.45% | 14.33% |
| Operating Income | -6.52% | -0.79% | -14.35% | 14.60% | 18.93% |
| Income Before Tax | -17.43% | -13.33% | -13.60% | 13.90% | 17.33% |
| Income Tax Expenses | 91.45% | 85.63% | 220.00% | 148.97% | -34.79% |
| Earnings from Continuing Operations | -18.12% | -14.33% | -15.64% | 12.45% | 17.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.12% | -14.33% | -15.64% | 12.45% | 17.54% |
| EBIT | -6.52% | -0.79% | -14.35% | 14.60% | 18.93% |
| EBITDA | -7.06% | -1.17% | -14.74% | 14.52% | 18.93% |
| EPS Basic | 12.50% | 20.45% | 33.79% | 63.48% | 70.84% |
| Normalized Basic EPS | 21.53% | 28.39% | 34.83% | 64.13% | 70.92% |
| EPS Diluted | 12.51% | 20.46% | 33.80% | 63.48% | 70.84% |
| Normalized Diluted EPS | 21.53% | 28.39% | 34.83% | 64.13% | 70.92% |
| Average Basic Shares Outstanding | 34.56% | 40.87% | 54.97% | 83.96% | 133.71% |
| Average Diluted Shares Outstanding | 34.56% | 40.87% | 54.97% | 83.96% | 133.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |